

## **Scientific Advisory Board**

### **Kenneth J. Pienta, M.D.**

Dr. Pienta is the Donald S. Coffey professor of urology and professor of oncology and pharmacology and molecular sciences at the Johns Hopkins University School of Medicine, and also serves as the director of research at the Brady Urological Institute. He is widely recognized for his expertise and leadership in prostate cancer research including the development of novel chemotherapeutic programs in prostate cancer and is a leading authority in translational research and has studied the role of the tumor microenvironment extensively.

### **Suresh Mohla Ph.D.**

Dr. Mohla was in the senior ranks of cancer research at the National Cancer Institute for 26 years, specializing primarily in the tumor microenvironment and various aspects thereof including inflammation, stem cells, angiogenesis, lymphangiogenesis, exosomes, metastasis, tumor dormancy and mechanisms of hormone refractory cancers, He has actively promoted transdisciplinary research in emerging scientific areas such as these; successful creation of the new NCI Network on Tumor Microenvironment, and he served as the Program Director for the Tumor Microenvironment Network (TMEN) Consortium for 10 years, served as associate editor of J Cellular Biochemistry and Cancer Microenvironment, He was a member of the Federal working Group on Bone Diseases – a transdisciplinary group. He was actively involved in scientific program committees of several national and international symposia including Skeletal Complications of Malignancy, and Chaired the International Symposium on Hormonal Oncogenesis. He was a member of the Steering Committee of the AACR Working Group on Tumor Microenvironment and is a member Emeritus of the AACR.

### **Brian Leyland-Jones M.D.**

Dr. Leyland-Jones is the Vice President of Molecular and Experimental Research at the Avera Cancer Institute and the Director of the Darwin Foundation. He has lead major changes in breast cancer clinical trials and treatments, as well as his ongoing focus on how genomics plays a vital role in the fight against breast cancer. As the Director of the Darwin Foundation (formerly the Consortium for Clinical Diagnostics), Dr. Leyland-Jones is partnering with scientists at research institutions and biopharmaceutical companies who are dedicated to facilitating genomic research and diagnostics.

### **Sujuan Ba, Ph.D.**

Dr. Ba currently serves as President and CEO of the National Foundation for Cancer Research where she oversees fundraising, financial planning, scientific direction and partnership development. She established the National Foundation for Cancer Research as a powerful

network of research centers and laboratories worldwide which has enabled NFCR Scientists to work collaboratively across disciplinary, institutional, and geographic boundaries.

**Richard Saul Ph.D.**

Company Representative

See Biography Above Under Management Team